Corcept Therapeutics Inc (CORT): Total Liabilities
$188.85M
As of 2025-12-31
$182.93M
As of 2026-06-30
+32.3%
3-year compound annual growth
+31.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $188.85M | +17.3% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $160.96M | +40.2% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $114.81M | +40.7% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $81.59M | +70.2% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $47.95M | -0.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $48.39M | +17.7% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $41.13M | +14.8% | 2021-02-23, Balance as of period end |
| 2018-12-31 | $35.81M | +21.1% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $29.57M | n/a | 2019-02-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $401.41M | +18.0% |
Compare CORT, EBS, COLL, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗